DRKS00028182
Completed
Not Applicable
Prospective, multi-centre, non-interventional safety trial to collect real-world data on the safety of immunotherapy with Depigoid® Katze in patients with allergic rhinitis/rhino-conjunctivitis with or without controlled asthma due to feline epithelia - LETI MIAU-KAT 2022
ETI Pharma GmbH0 sites102 target enrollmentMarch 14, 2022
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- allergic rhinitis/rhino-conjunctivitis with or without controlled asthma due to feline epithelia
- Sponsor
- ETI Pharma GmbH
- Enrollment
- 102
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients aged \= 12 years suffering from persistent moderate to severe allergic rhinitis and/or rhino\-conjunctivitis with or without controlled asthma caused by clinically relevant sensitisation to cats, demonstrated by a positive skin prick test (wheal diameter \= 3 mm) for Felix domesticus animal epithelia.
- •The patients have an indication for subcutaneous immunotherapy based on their symptoms and findings and, together with their doctor, chose treatment with Depigoid® Katze in accordance with standard clinical practice.
- •The patients have understood and signed the declaration of consent form for participation and use of patient\-related data in this non\-interventional safety study.
- •Concomitant asthma must be under control and stable as per the guidelines in the SmPC (no exacerbations within 3 months prior to inclusion in the study).
Exclusion Criteria
- •not applicable
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
A Observational non-interventional Post Marketing Surveillance (PMS) Study of RituxiRelTM RN(Rituximab)in Patients with Pemphigus VulgarisHealth Condition 1: L088- Other specified local infections of the skin and subcutaneous tissueCTRI/2020/06/025819Reliance Life Sciences Pv Ltd
Not yet recruiting
Phase 4
A Non-interventional, observational Post Marketing Surveillance (PMS) Study of AdaliRelTM (Adalimumab) in Patients With Active Rheumatoid arthritis.CTRI/2020/04/024644Reliance Life Sciences Pv Ltd
Recruiting
Phase 4
A post marketing surveillance study to evaluate the safety and tolerability of Gaviscon Double Action Oral Suspension and Gaviscon Double Action Tablets in patients with Gastroesophageal Reflux DiseaseHealth Condition 1: K210- Gastro-esophageal reflux disease with esophagitisCTRI/2024/02/062711Reckitt Benckiser Healthcare
Suspended
Not Applicable
A NON-INTERVENTIONAL, MULTI-CENTER, NON?RANDOMISED PATIENT REGISTRY FOR POST?MARKETING SURVEILLANCE OF MULTIPLE ORGAN DIALYSISMultiple Organ FailureN17K72E87Acute renal failureHepatic failure, not elsewhere classifiedOther disorders of fluid, electrolyte and acid-base balanceDRKS00017068ADVITOS GmbH282
Not yet recruiting
Phase 4
A research study to understand how oral semaglutide works in people with type 2 diabetes in IndiaHealth Condition 1: E11- Type 2 diabetes mellitusCTRI/2023/02/049724ovo Nordisk AS